Five peptide storefronts, five disclaimers, one identical FDA conclusion

ON THIS PAGE

1. Key findings
2. One count, five times
3. Five disclaimers, one conclusion
4. Four diluents, one calculator
5. The codes were decoded, or never used
6. Where this publication already had a record
7. What a letter tells a buyer, and what it does not
8. Limitations
9. Sources

Five storefronts wrote the same disclaimer five different ways. The sentence the agency wrote after quoting it is identical in all five, to the word. That is the whole finding of the August 24 batch, and it is more useful to a reader than a general account of a crackdown, because it says which variable the agency was not testing.

The recipients were Peak Performance Peptides, Peptide Partners LLC, NuScience Peptides LLC, Royal Peptides LLC, and TXP Innovations LLC dba Tex Peptides. The letters were posted together on September 1, 2026 and all five carry the same issue date. Read against the seven letters posted in April, covered in the March 31 letters, the batch extends one theory by a single sentence and leaves the rest untouched.

One count, five times

Every letter runs one violation heading. Under "Violations of the Federal Food, Drug, and Cosmetic Act" each of the five carries the same subheading, "Unapproved New Drug Violations," and each cites sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). On the five letters as posted and read on September 7, 2026, that is the only violation heading any of them carries: no misbranding count, and no finding about the identity, the composition or the manufacture of anything sold. The charge is what the storefront published about its own products, and the evidence is the page it published.

Each letter also dates its own evidence. All five say violations were identified and documented during a review of the firm's website in July 2026. Five site reviews in one month, five letters on one date, one posting day. The batching is deliberate.

Five disclaimers, one conclusion

Each letter opens the intended-use passage by quoting the storefront's own labeling back at it, introduced in every case with "Despite statements on your product labeling marketing your products." The words quoted differ at every one of the five, because the storefronts wrote them differently:

• Peak Performance Peptides: "research use only" and "not for human consumption"
• Peptide Partners LLC: "for research use only" and "not for human or veterinary use"
• NuScience Peptides LLC: "for laboratory, research, and analytical use" and "not intended for human or veterinary use"
• Royal Peptides LLC: "for research use only" and "not for human or animal consumption"
• TXP Innovations LLC dba Tex Peptides: "research use only", "for research and laboratory use only", and "not for human or veterinary use"

All five are then answered with the same finding: "evidence obtained from your website establishes that your products are intended to be drugs for human use." The letters locate the test in a regulation rather than in the label, listing their examples as "evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs."

A storefront comparing its own footer against those five formulations, looking for the one that sits far enough from human use, is solving a problem the agency did not pose. None of the five wordings did any work. What the letters quote as evidence is the product copy above the footer, not the footer.

Four diluents, one calculator

In four of the five, the diluent is not background. It is one of the cited products, named in the same list as the peptides and given its own one-sentence holding. Peak Performance Peptides: "Therefore, your 'Bac water' is a drug." Peptide Partners: "Therefore, your 'Reconstitution Solution (BAC)' is a drug." NuScience Peptides: "Therefore, your 'Bacteriostatic water for Peptides (BAC Water)' is a drug." TXP Innovations: "Therefore, your 'Bacteriostatic Water 0.9% Benzyl Alcohol (10 ml)' is a drug." Four catalog names, one holding, and it is the same holding the agency reached in the March 31 batch.

Royal Peptides LLC is the exception, and it is the one worth reading closely. Its letter cites seven products and no diluent among them. The means-to-prepare finding arrives instead as this:

you market bacteriostatic water alongside a "peptide guide" and "peptide calculator," resources that collectively provide the means to prepare an injectable drug for human administration.

The NuScience letter runs the same construction with the calculator alone and no guide, in addition to citing its own bacteriostatic water product as a drug. In the other three the sentence is narrower: bacteriostatic water marketed "as a solvent for reconstituting your products, thus, providing the means to prepare an injectable drug for human administration."

So a free informational page now sits inside the agency's evidence sentence. The distinction matters and is worth stating precisely: the guide and the calculator are named as part of what supplies the means, not as unapproved drugs of their own, and no letter in this batch cites a calculator as a product. But the sentence has widened from an item on the invoice to a resource on the site, and that widening does not appear in this publication's reading of the March 31 batch.

The codes were decoded, or never used

Coded catalog names survived nothing here. Royal Peptides' letter never needed the step: its cited products are "Tirzepatide," "Semaglutide," "Retatrutide," "SS-31 (Elamipretide)," "PT-141," "Tesamorelin," and "BIMORELIN," with no codes at all. Peak Performance's single coded item, "GLP-3R," carries its decode inside the letter as retatrutide. Peptide Partners and TXP Innovations each have three GLP-class codes cited with the compound printed beside them. NuScience is the only partial case: "GLP-3 RT (Retatrutide) Research Peptide" is decoded, while "GLP-2 Tirz Peptide" and "GLP-1 Sema Research Peptide" are cited under their catalog names, and that letter never states what "GLP-2 Tirz" is.

The catalogs are not interchangeable either. NuScience's letter is the longest at nine cited products and the only one naming survodutide, mazdutide and a "Tesamorelin Ipamorelin Blend." Royal Peptides' is the only one naming "BIMORELIN." Semaglutide, retatrutide, tesamorelin and PT-141 appear in all five. SS-31 appears in four, absent only from NuScience.

Where this publication already had a record

Terminus keeps a ledger record on two of these five businesses, and in both cases the two documents can be read against each other. The ledger entry for Tex Peptides is dated 2026-08-24, the same date the letter carries and eight days before the letter was posted, and it was made from texpeptide.com, the site the letter names.

On the disclaimer the two agree. The ledger records research-use-only language "present in a 21-and-over entry gate, in a banner reading 'FOR RESEARCH AND LABORATORY USE ONLY, NOT FOR HUMAN OR VETERINARY USE', and in the footer of every page." The letter quotes three formulations: "research use only", "for research and laboratory use only", and "not for human or veterinary use". The ledger's banner text and two of the letter's three quoted formulations are word for word the same, from two records of the same storefront made independently.

On the codes they diverge, in a way that shows the decode happening. The ledger's price list records the catalog as the storefront printed it: "GLP-3 RT 10mg $100.00 and 20mg $200.00, GLP-2 TRZ 15mg $100.00 and 30mg $200.00, GLP-1 SEM 10mg $75.00 and 20mg $150.00." Codes, no compound names. The letter cites the same three items as "Semaglutide (GLP-1 SEM)," "Tirzepatide (GLP-2 TRZ)," and "Retatrutide (GLP-3 RT)."

The ledger also holds material the letter does not reach. It records that both retatrutide product pages published a chemical profile whose formula, weight, sequence and CAS number are BPC-157 identifiers rather than retatrutide's, while the vendor's own laboratory document for that item reads Retatrutide, and that the semaglutide and tirzepatide pages carry correct identifiers. It records six laboratory documents published against a 36-product catalog, none of them newer than September 2025. None of that appears in the warning letter. The letter was not looking there.

The second record is on NuScience Peptides, dated 2026-08-20, four days before the letter it now sits beside. It bears directly on the decode question. The ledger's summary of that storefront reads: "the GLP-1 class fronted under code names (GLP-1 SM, GLP-2 TZ, GLP-3 RT) while the same pages print the identifying CAS numbers." Its price rows resolve two of those codes on that basis, semaglutide by CAS 910463-68-2 and retatrutide by CAS 2381089-83-2. The agency's letter, which cites the same class under longer catalog names, decodes only the retatrutide item. It never says what "GLP-2 Tirz" is. The storefront's own pages, on that read, said more than the letter does.

That ledger entry also runs past the letter's edge in the same direction the Tex Peptides one does. It records, under "Could not verify," that no lot number, no analytical method description, no test date, no purity figure and no analyst or laboratory identity was recoverable from inside either certificate PDF. That is a documentation observation, dated, made independently, and absent from the warning letter for the same reason: a warning letter in this batch is not a documentation audit.

What a letter tells a buyer, and what it does not

A letter in this batch is evidence about one thing: how a storefront markets itself. It is not a finding about the material in a vial, and reading it as one gets the exposure backwards in both directions. Whatever documentation these five publish, the letters neither dispute it nor endorse it, because a documentation question is not the question any of the five asks.

What the letters do carry for someone evaluating a supplier is continuity risk. Each gives fifteen business days to respond, and each carries the same sentence about regulatory or legal action without further notice, naming seizure and injunction. A storefront running that clock can keep taking orders with nothing visible changing, which is the failure mode described in how vendors disappear. The screening behind the vendor check flags human-use marketing language for the same reason the agency quoted it: it is the thing on the page that the disclaimer underneath does not answer.

Limitations

Four things this piece does not establish. A warning letter states the agency's position and opens a window to respond; it is not an adjudication, and this piece reports no reply from any of the five recipients because it establishes none. The letters were built from website reviews conducted in July 2026, and none of those five sites was fetched for this piece, so nothing here describes how any of them reads today. Terminus holds a ledger record on two of the five and none on the other three, so Tex Peptides and NuScience Peptides are described in more detail than Peak Performance Peptides, Peptide Partners LLC or Royal Peptides LLC by accident of coverage rather than by judgment. And every reading above rests on the posted text of the five letters; the underlying correspondence, the firms' replies, and any action after September 1 sit outside it.

The theory grew by one sentence between March and August. Whether it grows again is what the next posting day answers.

Sources

The five warning letters, at fda.gov, each dated August 24, 2026, each posted September 1, 2026, each fetched and read on 2026-09-07: Peak Performance Peptides, MARCS-CMS 735127; Peptide Partners LLC, MARCS-CMS 735063; NuScience Peptides LLC, MARCS-CMS 733652; Royal Peptides LLC, MARCS-CMS 734884; TXP Innovations LLC dba Tex Peptides, MARCS-CMS 735067. Every quotation above is from those five documents as posted at those URLs on the fetch date. The earlier batch this piece reads against carries its own primary sources in the March 31 letters. Every observation about Tex Peptides and NuScience Peptides that is not in their warning letters comes from this publication's own vendor ledger entries for those storefronts, recorded 2026-08-24 and 2026-08-20 and published at the Tex Peptides ledger page and the NuScience Peptides ledger page.